NGQ1 Stock Chart & Stats
€0.69
-€0.01(-1.85%)
At close: 4:00 PM EST
€0.69
-€0.01(-1.85%)
Day’s Range― - ―
52-Week Range€0.55 - €0.84
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€8.38M
Enterprise Value€9.70M
Total Cash (Recent Filing)€1.54M
Total Debt (Recent Filing)€803.00K
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding10,436,313
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.92
Price to Sales (P/S)0.41
P/FCF Ratio-21.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Specialty FranchiseA clear, durable focus on cardiovascular therapies and commercialization in the U.S. and Canada concentrates resources on a defined addressable market. That specialization supports targeted sales, regulatory know-how and repeatable prescription revenue streams over multiple quarters as product adoption matures.
Top-line MomentumSustained revenue growth indicates improving market uptake of marketed drugs and commercial traction. Durable top-line expansion provides a platform to leverage fixed selling costs, support incremental profitability, and fund reinvestment if management maintains disciplined commercial execution.
Low Financial LeverageA conservative capital structure with minimal debt materially reduces refinancing and interest burden risk. Low leverage preserves operational flexibility during prolonged cash outflows, giving management time to correct margins or pursue non-dilutive options before needing urgent external financing.
Bears Say
Sharp Margin DeteriorationA steep, persistent decline in gross margin signals worsening product economics, pricing or rebate pressure. Lower gross margins weaken the company's ability to cover fixed selling and R&D costs, making a sustainable return to profitability harder without structural improvements to pricing, cost or mix.
Negative Cash GenerationOngoing negative operating and free cash flow erode liquidity and increase dependency on external funding or equity issuance. Over months this constrains reinvestment in commercial activities, weakens negotiating leverage with payors, and raises the risk of operational cutbacks if cash deficits persist.
Erosion Of Shareholder Equity & ReturnsShrinking equity and sharply negative ROE reflect sustained losses that erode the capital base. This reduces the buffer against adverse shocks and limits internal capacity to fund growth or absorb setbacks, increasing the need for dilutive financing or strategic capital actions if losses continue.
Medicure News
NGQ1 FAQ
What was Medicure Inc’s price range in the past 12 months?
Medicure Inc lowest stock price was €0.55 and its highest was €0.84 in the past 12 months.
What is Medicure Inc’s market cap?
Medicure Inc’s market cap is €8.38M.
When is Medicure Inc’s upcoming earnings report date?
Medicure Inc’s upcoming earnings report date is Aug 26, 2026 which is in 22 days.
How were Medicure Inc’s earnings last quarter?
Currently, no data Available
Is Medicure Inc overvalued?
According to Wall Street analysts Medicure Inc’s price is currently Overvalued.
Does Medicure Inc pay dividends?
Medicure Inc does not currently pay dividends.
What is Medicure Inc’s EPS estimate?
Medicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicure Inc have?
Medicure Inc has 10,436,313 shares outstanding.
What happened to Medicure Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Medicure Inc?
Currently, no hedge funds are holding shares in DE:NGQ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicure Inc
Medicure Inc. is a biopharmaceutical firm focused on developing, researching, and commercializing therapeutic solutions for cardiovascular conditions across Canada and the United States. Its product portfolio includes AGGRASTAT, an injectable glycoprotein GP IIb/IIIa receptor antagonist prescribed for acute coronary syndromes, such as unstable angina and non-Q-wave myocardial infarction. The company also provides ZYPITAMAG, a medication used to manage primary hyperlipidemia and mixed dyslipidemia. Additionally, Medicure offers the ReDS system, a non-invasive medical device designed to measure lung fluid levels, aiding in the management of congestive heart failure. Another key offering is Sodium Nitroprusside injection, utilized for rapidly lowering blood pressure during hypertensive crises in both adult and pediatric patients, inducing controlled hypotension for surgical bleeding reduction, and treating acute congestive heart failure. These products are made available through both retail pharmacy networks and online platforms. Established in 1997, Medicure Inc. is headquartered in Winnipeg, Canada.
Technical Analysis
Aequus Pharmaceuticals
―
Pharmadrug
―
Mountain Valley MD
―
Medexus Pharmaceuticals Inc
―
Xebra Brands Ltd.
―